Pleuroparenchymal Fibroelastosis impact in Idiopathic Pulmonary Fibrosis outcomes
N. Faria (Porto, Portugal), S. Dias (Porto, Portugal), M. Silva (Porto, Portugal), D. Carvalho (Porto, Portugal), A. Carvalho (Porto, Portugal), P. Mota (Porto, Portugal), N. Melo (Porto, Portugal), H. Bastos (Porto, Portugal), A. Alexandre (Porto, Portugal), C. Moura (Porto, Portugal), S. Guimarães (Porto, Portugal), O. Sokhatska (Porto, Portugal), R. Cunha (Porto, Portugal), J. Pereira (Porto, Portugal), A. Morais (Porto, Portugal)
Source: International Congress 2022 – New tools for the diagnosis of interstitial lung diseases
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Faria (Porto, Portugal), S. Dias (Porto, Portugal), M. Silva (Porto, Portugal), D. Carvalho (Porto, Portugal), A. Carvalho (Porto, Portugal), P. Mota (Porto, Portugal), N. Melo (Porto, Portugal), H. Bastos (Porto, Portugal), A. Alexandre (Porto, Portugal), C. Moura (Porto, Portugal), S. Guimarães (Porto, Portugal), O. Sokhatska (Porto, Portugal), R. Cunha (Porto, Portugal), J. Pereira (Porto, Portugal), A. Morais (Porto, Portugal). Pleuroparenchymal Fibroelastosis impact in Idiopathic Pulmonary Fibrosis outcomes. 3427
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|